Ivan Pavlovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ivan Pavlovic has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Joachim Burman
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
3 shared publications Anna Wiberg
Translational Neurology, Department of Medical Sciences Uppsala University Uppsala Sweden
2 shared publicationsMalin Müller
Translational Neurology, Department of Medical Sciences Uppsala University Uppsala Sweden
2 shared publicationsAnders Larsson
Clinical Chemistry, Department of Medical Sciences Uppsala University Uppsala Sweden
1 shared publication- Anna Wiberg
Translational Neurology, Department of Medical Sciences, Uppsala University
1 shared publication Christina Zjukovskaja
Neurology, Department of Medical Sciences, Uppsala University, 752 37 Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
- 14 October 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (3) , 442-452
The MMP ‐9/ TIMP ‐1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation
Objectives: To evaluate the utility of cerebrospinal fluid (CSF) biomarkers—matrix metalloproteinase‐9 (MMP‐9), tissue inhibitor of metalloproteinases‐1 (TIMP‐1), the MMP‐9/TIMP‐1 ratio, and osteopontin (OPN)—as indicators of blood–brain barrier (BBB) integrity and disease activity in people with relapsing–remitting multiple sclerosis (pwMS), and to assess their changes following autologous hematopoietic stem cell transplantation (aHSCT). Methods: CSF samples from pwMS treated with aHSCT ( n = 43) and healthy controls ( n = 32) were analyzed for MMP‐9, TIMP‐1, and OPN concentrations using ELISA and electrochemiluminescence assays. Lumbar punctures were performed at baseline and at 1, 2, and 3–5 years post‐aHSCT. Biomarker findings were compared with standard CSF parameters, prior treatments, and MRI data. Results: MMP‐9/TIMP‐1 ratios and OPN levels were significantly elevated in pwMS compared to controls, particularly in those with gadolinium‐enhancing lesions or on first‐line therapies. Both biomarkers declined significantly after aHSCT and remained low during follow‐up. The MMP‐9/TIMP‐1 ratio showed superior discriminatory capacity and correlated with inflammatory CSF markers. Interpretation: CSF MMP‐9/TIMP‐1 ratio and OPN are elevated in MS and decrease following aHSCT, reflecting reduced inflammation and restored BBB integrity. These biomarkers may support disease monitoring and therapeutic evaluation.
- 14 October 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (3) , 442-452
Open AccessThe MMP ‐9/ TIMP ‐1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation
Objectives: To evaluate the utility of cerebrospinal fluid (CSF) biomarkers—matrix metalloproteinase‐9 (MMP‐9), tissue inhibitor of metalloproteinases‐1 (TIMP‐1), the MMP‐9/TIMP‐1 ratio, and osteopontin (OPN)—as indicators of blood–brain barrier (BBB) integrity and disease activity in people with relapsing–remitting multiple sclerosis (pwMS), and to assess their changes following autologous hematopoietic stem cell transplantation (aHSCT). Methods: CSF samples from pwMS treated with aHSCT ( n = 43) and healthy controls ( n = 32) were analyzed for MMP‐9, TIMP‐1, and OPN concentrations using ELISA and electrochemiluminescence assays. Lumbar punctures were performed at baseline and at 1, 2, and 3–5 years post‐aHSCT. Biomarker findings were compared with standard CSF parameters, prior treatments, and MRI data. Results: MMP‐9/TIMP‐1 ratios and OPN levels were significantly elevated in pwMS compared to controls, particularly in those with gadolinium‐enhancing lesions or on first‐line therapies. Both biomarkers declined significantly after aHSCT and remained low during follow‐up. The MMP‐9/TIMP‐1 ratio showed superior discriminatory capacity and correlated with inflammatory CSF markers. Interpretation: CSF MMP‐9/TIMP‐1 ratio and OPN are elevated in MS and decrease following aHSCT, reflecting reduced inflammation and restored BBB integrity. These biomarkers may support disease monitoring and therapeutic evaluation.
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (1) , e200345
Micro-RNA Signature in CSF Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
MicroRNAs (miRNAs) are regulators of gene expression and have been reported to be dysregulated in people with multiple sclerosis (pwMS). Autologous hematopoietic stem cell transplantation (aHSCT) is an immune-ablative treatment intervention for pwMS. Currently, it is unknown if aHSCT affects expression levels of miRNAs in CSF. We explored the ability of circulating miRNA to discriminate between pwMS and healthy controls (HCs) and investigated whether these miRNAs were affected by treatment with aHSCT. Using quantitative reverse transcription PCR, 87 miRNAs were analyzed in CSF samples of a discovery cohort (baseline: 4 & HC: 4). The top 22 miRNAs discriminating between pwMS and HCs were then analyzed in 187 CSF samples of a validation cohort (pwMS: 50, HC: 32). Samples, failing quality control or being follow-ups to baseline samples with quality control issues, were excluded from further analyses. The remaining 133 samples (HC: 29, MS: baseline: 33, 1 year: 30, 2 years: 26, 3-5 years: 15) were analyzed for expression of the top 22 miRNAs. Twelve miRNAs were dysregulated in pwMS compared with HC (q < 0.05). Associations with clinical and analytical parameters were observed in relation to all 12 miRNAs; however, a cluster of 4 miRNAs (miR-16-5p, miR-21-5p, miR-150-5p, and miR-146a-5p) with strong correlations (r > 0.60, p < 0.001) with multiple parameters was identified. Of the 12 miRNAs, 8 were differentially expressed in pwMS with gadolinium-enhancing lesions at baseline and 4 by prior disease-modifying treatment class (p < 0.05). These 4 miRNAs correlated strongly with each other, decreased after aHSCT, and remained low throughout the follow-up period (p < 0.05). Target and pathway analysis of these revealed association with biological processes affecting cytokine production, inflammatory response, and regulation of myelin maintenance. miRNAs are dysregulated in CSF from pwMS and particularly in patients with less effective treatments and/or higher inflammatory disease activity. A 4-miRNA signature with elevated expression of miR-16-5p, miR-21-5p, miR-150-5p, and miR-146a-5p was recurring in multiple analyses. After intervention with aHSCT, the expression levels approached the levels of the HCs, suggesting a potent treatment effect.
- 1 January 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (1) , e200345
Open AccessMicro-RNA Signature in CSF Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
MicroRNAs (miRNAs) are regulators of gene expression and have been reported to be dysregulated in people with multiple sclerosis (pwMS). Autologous hematopoietic stem cell transplantation (aHSCT) is an immune-ablative treatment intervention for pwMS. Currently, it is unknown if aHSCT affects expression levels of miRNAs in CSF. We explored the ability of circulating miRNA to discriminate between pwMS and healthy controls (HCs) and investigated whether these miRNAs were affected by treatment with aHSCT. Using quantitative reverse transcription PCR, 87 miRNAs were analyzed in CSF samples of a discovery cohort (baseline: 4 & HC: 4). The top 22 miRNAs discriminating between pwMS and HCs were then analyzed in 187 CSF samples of a validation cohort (pwMS: 50, HC: 32). Samples, failing quality control or being follow-ups to baseline samples with quality control issues, were excluded from further analyses. The remaining 133 samples (HC: 29, MS: baseline: 33, 1 year: 30, 2 years: 26, 3-5 years: 15) were analyzed for expression of the top 22 miRNAs. Twelve miRNAs were dysregulated in pwMS compared with HC (q < 0.05). Associations with clinical and analytical parameters were observed in relation to all 12 miRNAs; however, a cluster of 4 miRNAs (miR-16-5p, miR-21-5p, miR-150-5p, and miR-146a-5p) with strong correlations (r > 0.60, p < 0.001) with multiple parameters was identified. Of the 12 miRNAs, 8 were differentially expressed in pwMS with gadolinium-enhancing lesions at baseline and 4 by prior disease-modifying treatment class (p < 0.05). These 4 miRNAs correlated strongly with each other, decreased after aHSCT, and remained low throughout the follow-up period (p < 0.05). Target and pathway analysis of these revealed association with biological processes affecting cytokine production, inflammatory response, and regulation of myelin maintenance. miRNAs are dysregulated in CSF from pwMS and particularly in patients with less effective treatments and/or higher inflammatory disease activity. A 4-miRNA signature with elevated expression of miR-16-5p, miR-21-5p, miR-150-5p, and miR-146a-5p was recurring in multiple analyses. After intervention with aHSCT, the expression levels approached the levels of the HCs, suggesting a potent treatment effect.
- Open Access
- 3 February 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 84, 105482
Cerebrospinal fluid mtDNA concentrations are increased in multiple sclerosis and were normalized after intervention with autologous hematopoietic stem cell transplantation
- 3 February 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 84, 105482
Open AccessCerebrospinal fluid mtDNA concentrations are increased in multiple sclerosis and were normalized after intervention with autologous hematopoietic stem cell transplantation